Physiogenomic association of statin-related myalgia to serotonin receptors

Muscle and Nerve

Volumn 36, Issue 3, 2007, Pages 329-335

  Ruaño, Gualberto ^a   Thompson, Paul D ^b   Windemuth, Andreas ^a   Seip, Richard L ^a,b   Dande, Amit ^b   Sorokin, Alexey ^b   Kocherla, Mohan ^a   Smith, Andrew ^c   Holford, Theodore R ^d   Wu, Alan H B ^c  

^a Genomas Inc   (United States)

^b HARTFORD HOSPITAL   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Myalgia; Nociception; Physiogenomics; Serotonin receptors; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SIMVASTATIN;

ADULT; AGED; ARTICLE; FEMALE; GENE; GENOME ANALYSIS; HTR1D GENE; HTR2A GENE; HTR2C GENE; HTR3A GENE; HTR3B GENE; HTR5A GENE; HTR6 GENE; HTR7 GENE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NOCICEPTION; NOCICEPTIVE STIMULATION; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A4 GENE;

AGED; AGED, 80 AND OVER; FEMALE; GENOMICS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MUSCULAR DISEASES; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; PYRROLES; RECEPTORS, SEROTONIN; SIMVASTATIN;

EID: 34548254518     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20871     Document Type: Article

References (26)

1. Abbott FV, Hong Y, Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology 1996;35:99-110.
2. Ahn AH, Basbaum AI. Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain. J Neurosci 2006;26:8332-8338.
3. Albano C, Cupello A, Mainardi P, Scarrone S, Favale E. Successful treatment of epilepsy with serotonin reuptake inhibitors: proposed mechanism. Neurochem Res 2006;31:509-514.
4. Arora R, Liebo M, Maldonado F. Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther 2006;11:105-112.
5. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001;24:258-272.
6. Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. Drugs Today (Barcel) 2005;41:267-293.
7. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004;56:371-381.
8. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006;97:6C-26C.
9. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(suppl):III-50-57.
10. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 1995;57:289-300.
11. Benjamini Y, Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat 2000;25:60-83.
12. Brown CC, Fears TR. Exact significance levels for multiple binomial testing with application to carcinogenicity screens. Biometrics 1981;37:763-774.
13. Campbell WW. Statin myopathy: the iceberg or its tip? Muscle Nerve 2006;34:387-390.
14. Doly S, Fischer J, Brisorgueil MJ, Verge D, Conrath M. 5-HT5A receptor localization in the rat spinal cord suggests a role in nociception and control of pelvic floor musculature. J Comp Neurol 2004;476:316-329.
15. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL, et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003;68:69-78.
16. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202.
17. Gotto AM Jr. Statins, cardiovascular disease, and drug safety. Am J Cardiol 2006;97:3C-5C.
18. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006;55:551-557.
19. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27-55.
20. Hamilton-Craig I. Statin-associated myopathy. Med J Austral 2001;175:486-489.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
22. Heyse J, Rom D. Adjusting for multiplicity of statistical tests in the analysis of carcinogenicity studies. Biometr J 1988;30:883-896.
23. Ikeda M, Iwata N, Kitajima T, Suzuki T, Yamanouchi Y, Kinoshita Y, et al. Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology 2006;31:866-871.
24. Koeppe C, Schneider C, Thieme K, Mense S, Stratz T, Muller W, et al. The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol 2004;119(suppl):24-27.
25. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996;66:47-56.
26. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C.